CO2017009992A2 - Derivados de benzimidazoles como inhibidores de bromodominios - Google Patents
Derivados de benzimidazoles como inhibidores de bromodominiosInfo
- Publication number
- CO2017009992A2 CO2017009992A2 CONC2017/0009992A CO2017009992A CO2017009992A2 CO 2017009992 A2 CO2017009992 A2 CO 2017009992A2 CO 2017009992 A CO2017009992 A CO 2017009992A CO 2017009992 A2 CO2017009992 A2 CO 2017009992A2
- Authority
- CO
- Colombia
- Prior art keywords
- benzimidazole derivatives
- bromodomain inhibitors
- salts
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Compuestos de fórmula (I) y sales de los mismos, en la que R1, R2, R3, R4¬ son como se han definido en la presente memoria. Se ha encontrado que los Compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas de bromodominio a, por ejemplo, residuos de lisina acetilados y por lo tanto pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceres.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
| PCT/EP2016/055792 WO2016146738A1 (en) | 2015-03-19 | 2016-03-17 | Benzimidazole derivatives as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009992A2 true CO2017009992A2 (es) | 2018-01-05 |
Family
ID=53052091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009992A CO2017009992A2 (es) | 2015-03-19 | 2017-09-29 | Derivados de benzimidazoles como inhibidores de bromodominios |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10442786B2 (es) |
| EP (2) | EP3271349B1 (es) |
| JP (1) | JP6419990B2 (es) |
| KR (1) | KR102072850B1 (es) |
| CN (1) | CN107635989B (es) |
| AR (1) | AR103934A1 (es) |
| AU (1) | AU2016232217B2 (es) |
| BR (1) | BR112017019779B1 (es) |
| CA (1) | CA2979504C (es) |
| CL (1) | CL2017002332A1 (es) |
| CO (1) | CO2017009992A2 (es) |
| CR (1) | CR20170430A (es) |
| CY (1) | CY1121855T1 (es) |
| DK (1) | DK3271349T3 (es) |
| DO (1) | DOP2017000213A (es) |
| EA (1) | EA033594B1 (es) |
| ES (1) | ES2735417T3 (es) |
| GB (1) | GB201504689D0 (es) |
| HR (1) | HRP20191186T1 (es) |
| HU (1) | HUE044414T2 (es) |
| IL (1) | IL254318B (es) |
| LT (1) | LT3271349T (es) |
| MA (2) | MA41778A (es) |
| ME (1) | ME03485B (es) |
| MX (1) | MX2017012023A (es) |
| PE (1) | PE20180032A1 (es) |
| PH (1) | PH12017501620A1 (es) |
| PL (1) | PL3271349T3 (es) |
| PT (1) | PT3271349T (es) |
| RS (1) | RS59056B1 (es) |
| SG (1) | SG11201707356QA (es) |
| SI (1) | SI3271349T1 (es) |
| TW (1) | TW201706257A (es) |
| UY (1) | UY36589A (es) |
| WO (1) | WO2016146738A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN108290856A (zh) | 2015-08-11 | 2018-07-17 | 尼奥迈德研究所 | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| IL257340B2 (en) | 2015-08-12 | 2023-10-01 | Neomed Inst | Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| EP3612522A4 (en) | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| EP3750885A4 (en) * | 2018-02-06 | 2021-10-27 | Shanghai Haihe Pharmaceutical Co., Ltd. | COMPOUND PRESENTING AN INHIBITORING ACTIVITY OF BET, ITS PREPARATION PROCESS AND ITS USE |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| WO2020190780A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| AU2020264106A1 (en) * | 2019-04-24 | 2021-12-23 | Convergene, Llc | Small molecule bromodomain inhibitors and uses thereof |
| US20220227709A1 (en) * | 2019-04-29 | 2022-07-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating schistosoma infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| KR101054325B1 (ko) | 2006-03-31 | 2011-08-04 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ４ 수용체 조절제로서의 벤조이미다졸―２―일 피리미딘 및 피라진 |
| EP2493310A4 (en) * | 2009-10-27 | 2014-03-12 | Glaxosmithkline Llc | BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| MY170236A (en) | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| CA2895905A1 (en) * | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| KR102244719B1 (ko) | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| US9662311B2 (en) * | 2013-06-21 | 2017-05-30 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/en active Application Filing
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko active IP Right Grant
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/en active Active
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja active Active
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh active Active
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt active IP Right Grant
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 CA CA2979504A patent/CA2979504C/en active Active
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/me unknown
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/en not_active Withdrawn
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-01 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009992A2 (es) | Derivados de benzimidazoles como inhibidores de bromodominios | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CO2019001871A2 (es) | Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| EA201500926A1 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| BR112016012781A2 (pt) | Novos métodos | |
| SV2016005316A (es) | Compuestos y composiciones para inducir condrogénesis | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| CR20160039A (es) | Imidazotiazol sulfonamidas como nematicidas | |
| UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| NI201500172A (es) | Composiciones farmacéuticas |